Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial

Lancet Respiratory Medicine
Apr 2021 Volume 9 Number 4 p319-434, e30-e46
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial
Tracey A Day, et al for the TBVPX-203 study team